Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes
- 11 August 2017
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (18) , 3118-3130
Abstract
Background and Purpose: One of the protective actions of angiotensin converting enzyme‐2 (ACE2) is the inactivation of angiotensin II. Expression and activity of ACE2 was reduced in glomeruli of diabetic patients and in animal models of diabetes. Recently the potential role of recombinant ACE2 administration in preventing diabetic nephropathy (DN) has been shown. Here we have tested the effects of the ACE2 activator, diminazene aceturate (DIZE), in a model of DN.Experimental Approach: Male Wistar rats were rendered diabetic using a single dose of streptozotocin (55 mg·kg−1, i.p.). After 4 weeks, diabetic animals were divided into experimental groups and treated with DIZE, at a low dose (5 mg·kg−1·day−1), a high dose (15 mg·kg−1·day−1) and the high dose with of the AT2 receptor antagonist PD123319 (10 mg·kg−1·day−1). At the end of the treatment , kidneys from all the groups were collected and processed separately for glomerular isolation, protein isolation, mRNA extraction and for immunohistochemical studies.Key Results: Treatment with DIZE restored ACE2 expression in glomeruli and increased expression of AT2 receptors in whole kidney and isolated glomeruli of diabetic animals. DIZE administration reduced angiotensin II levels and increased angiotensin‐(1–7) levels in diabetic kidney. However, PD123319 treatment reversed all these actions of DIZE.Conclusions and Implications: DIZE treatment reduced diabetes‐induced renal damage as shown by reduction of fibrosis and apoptosis. These protective actions of DIZE were blocked by the AT2 receptor antagonist. Taken together, these results suggest that DIZE protected against DN through the ACE2/angiotensin‐(1–7)/ AT2 receptor axis.Keywords
Funding Information
- Council for Scientific and Industrial Research (37(1644)/15/EMR-II)
This publication has 52 references indexed in Scilit:
- Diminazene Aceturate Enhances Angiotensin-Converting Enzyme 2 Activity and Attenuates Ischemia-Induced Cardiac PathophysiologyHypertension, 2013
- Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and DiseaseInternational Journal of Peptides, 2012
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Molecular mechanisms of the antagonistic action between AT1 and AT2 receptorsBiochemical and Biophysical Research Communications, 2010
- Human Recombinant ACE2 Reduces the Progression of Diabetic NephropathyDiabetes, 2009
- Renal and Retinal Effects of Enalapril and Losartan in Type 1 DiabetesNew England Journal of Medicine, 2009
- Renal ACE and ACE2 Expression in Early Diabetic RatsNephron Experimental Nephrology, 2008
- Glomerular Localization and Expression of Angiotensin-Converting Enzyme 2 and Angiotensin-Converting EnzymeJournal of the American Society of Nephrology, 2006
- Increased ACE 2 and Decreased ACE Protein in Renal Tubules From Diabetic MiceHypertension, 2004
- Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathyKidney International, 2003